259 related articles for article (PubMed ID: 38342825)
1. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract][Full Text] [Related]
2. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
Ren Y; Song J; Li X; Luo N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
[TBL] [Abstract][Full Text] [Related]
5. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY
Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838
[TBL] [Abstract][Full Text] [Related]
7. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
Cao Y; Li W; Wang Z; Pang H
Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
[TBL] [Abstract][Full Text] [Related]
8. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.
Matusz-Fisher A; Tan AR
Expert Opin Biol Ther; 2022 Mar; 22(3):385-395. PubMed ID: 34806498
[TBL] [Abstract][Full Text] [Related]
9. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
Liao L; Xu H; Zhao Y; Zheng X
Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
12. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
14. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
[TBL] [Abstract][Full Text] [Related]
15. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
17. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
[TBL] [Abstract][Full Text] [Related]
20. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]